JP2024508047A5 - - Google Patents

Info

Publication number
JP2024508047A5
JP2024508047A5 JP2023572670A JP2023572670A JP2024508047A5 JP 2024508047 A5 JP2024508047 A5 JP 2024508047A5 JP 2023572670 A JP2023572670 A JP 2023572670A JP 2023572670 A JP2023572670 A JP 2023572670A JP 2024508047 A5 JP2024508047 A5 JP 2024508047A5
Authority
JP
Japan
Application number
JP2023572670A
Other languages
Japanese (ja)
Other versions
JP2024508047A (ja
JPWO2022173531A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/011463 external-priority patent/WO2022173531A1/en
Publication of JP2024508047A publication Critical patent/JP2024508047A/ja
Publication of JP2024508047A5 publication Critical patent/JP2024508047A5/ja
Publication of JPWO2022173531A5 publication Critical patent/JPWO2022173531A5/ja
Pending legal-status Critical Current

Links

JP2023572670A 2021-02-10 2022-01-06 化合物、組成物、及びそれらの使用方法 Pending JP2024508047A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163147959P 2021-02-10 2021-02-10
US63/147,959 2021-02-10
US202163181917P 2021-04-29 2021-04-29
US202163181899P 2021-04-29 2021-04-29
US63/181,899 2021-04-29
US63/181,917 2021-04-29
PCT/US2022/011463 WO2022173531A1 (en) 2021-02-10 2022-01-06 Compounds, compositions, and methods of using thereof

Publications (3)

Publication Number Publication Date
JP2024508047A JP2024508047A (ja) 2024-02-21
JP2024508047A5 true JP2024508047A5 (https=) 2025-01-16
JPWO2022173531A5 JPWO2022173531A5 (https=) 2025-01-16

Family

ID=82837914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572670A Pending JP2024508047A (ja) 2021-02-10 2022-01-06 化合物、組成物、及びそれらの使用方法

Country Status (10)

Country Link
US (2) US20240173267A1 (https=)
EP (1) EP4291201A4 (https=)
JP (1) JP2024508047A (https=)
KR (1) KR20230155448A (https=)
AU (1) AU2022218642A1 (https=)
BR (1) BR112023015937A2 (https=)
CA (1) CA3207753A1 (https=)
IL (1) IL305064A (https=)
MX (1) MX2023009345A (https=)
WO (1) WO2022173531A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023091490A1 (en) * 2021-11-16 2023-05-25 Senda Biosciences, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2024050372A2 (en) * 2022-08-30 2024-03-07 Rejuvenation Technologies Inc. Compositions and methods for delivery of rna
EP4584252A1 (en) * 2022-09-11 2025-07-16 Barcode Nanotech Ltd. Ionizable lipids and compositions comprising same
EP4612284A2 (en) 2022-11-04 2025-09-10 Life Edit Therapeutics, Inc. Evolved adenine deaminases and rna-guided nuclease fusion proteins with internal insertion sites and methods of use
CN115932098B (zh) * 2022-12-14 2024-12-24 辅必成(上海)医药科技有限公司 一种用hplc法分离胆固醇、表胆甾醇和异胆固醇的方法
CN115677518B (zh) * 2023-01-05 2023-04-14 北京悦康科创医药科技股份有限公司 用于递送核酸的可电离阳离子脂质化合物和组合物及用途
US20240366521A1 (en) * 2023-01-17 2024-11-07 Qana Therapeutics Inc. Nanoparticles and methods of use
WO2024162304A1 (ja) * 2023-01-31 2024-08-08 アステラス製薬株式会社 環状アミンを有するカルバモイル脂質又はウレア脂質、それを含む脂質ナノ粒子、及び医薬組成物
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
CN118666726A (zh) * 2023-03-17 2024-09-20 尧唐(上海)生物科技有限公司 递送治疗剂的脂质化合物及其制备方法与应用
EP4704855A1 (en) * 2023-04-26 2026-03-11 Saliogen Therapeutics, Inc. Lipid nanoparticle (lnp) formulations
WO2025022367A2 (en) 2023-07-27 2025-01-30 Life Edit Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2025083619A1 (en) 2023-10-18 2025-04-24 Life Edit Therapeutics, Inc. Rna-guided nucleases and acive fragments and variants thereof and methods of use
CN117603064B (zh) * 2023-11-08 2025-09-16 上海凌凯科技股份有限公司 一种三(羟基烷基)甲基胺的制备方法及中间体
WO2025166238A1 (en) 2024-01-31 2025-08-07 Orna Therapeutics, Inc. Fast-shedding polyethylene glycol lipids
TW202546224A (zh) 2024-02-12 2025-12-01 美商生命編輯治療學公司 新穎的rna引導之核酸酶及用於聚合酶編輯之蛋白質
WO2026003754A1 (en) 2024-06-25 2026-01-02 Life Edit Therapeutics, Inc. Novel reverse transcriptases and uses thereof
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026029046A1 (ja) * 2024-07-30 2026-02-05 アステラス製薬株式会社 側鎖に環状基を有するウレア又はカーバメート脂質、その脂質ナノ粒子、及びその医薬組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2398918T3 (es) 2005-08-26 2013-03-22 Dupont Nutrition Biosciences Aps Un método y una ordenación para soportar verticalmente elementos de resistencia eléctrica pendientes
SI2049663T1 (sl) 2006-08-11 2015-12-31 Dow Agrosciences Llc Homologna rekombinacija, posredovana z nukleazo s cinkovim prstom
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
WO2010054108A2 (en) 2008-11-06 2010-05-14 University Of Georgia Research Foundation, Inc. Cas6 polypeptides and methods of use
MX337838B (es) 2008-11-07 2016-03-22 Dupont Nutrition Biosci Aps Secuencias de repetidos palindromicos cortos regularmente intercalados agrupados de bifidobacterias.
CN103261213A (zh) 2010-10-20 2013-08-21 杜邦营养生物科学有限公司 乳球菌CRISPR-Cas序列
KR102068107B1 (ko) 2011-04-27 2020-01-20 아미리스 인코퍼레이티드 게놈 변형 방법
WO2013016058A1 (en) * 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
KR102451116B1 (ko) * 2011-10-27 2022-10-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, n-말단 상에 관능화된 아미노산 유도체
US9593077B2 (en) * 2013-11-18 2017-03-14 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
KR102380363B1 (ko) 2014-11-18 2022-03-29 아크투루스 쎄라퓨틱스, 인크. Rna 전달을 위한 이온성 양이온 지질
EP3313449B1 (en) * 2015-06-24 2020-09-23 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
US10383952B2 (en) * 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10526284B2 (en) * 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2018183901A1 (en) * 2017-03-30 2018-10-04 The Government Of The United States Of America As Represented By The Secretary Of The Army Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines
WO2019046809A1 (en) * 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
JP2021512090A (ja) * 2018-01-30 2021-05-13 モデルナティーエックス, インコーポレイテッド 免疫細胞に薬剤を送達するための組成物及び方法
US12083224B2 (en) * 2018-03-30 2024-09-10 Arcturus Therapeutics, Inc. Lipid particles for nucleic acid delivery
EP3880812A4 (en) * 2018-11-13 2022-09-07 Oncorus, Inc. ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE
AU2020268388A1 (en) * 2019-05-07 2021-12-02 Modernatx, Inc. Polynucleotides for disrupting immune cell activity and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2024508047A5 (https=)
JP2024503623A5 (https=)
JP2024542188A5 (https=)
CL2025004061A1 (es) Filtro, componente de filtro y sistema de conectores de filtro con lengüetas de enclavamiento y elementos de retención
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BY13164U (https=)
BY13161U (https=)
CN307046202S (https=)
CN307044960S (https=)
CN307044403S (https=)
CN307044367S (https=)
CN307044317S (https=)
CN307047011S (https=)
BY23965C1 (https=)
BY23963C1 (https=)
CN307047478S (https=)
BY13175U (https=)
BY13174U (https=)
BY13172U (https=)
BY13170U (https=)
BY13169U (https=)
BY13168U (https=)
BY13166U (https=)
BY13167U (https=)